Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
Jul 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Guideline-based indicators for adult patients with myelodysplastic syndromes |
Aug 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients |
Nov 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
Apr 2023 |
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
Mar 2021 |
Blood cells, molecules and diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes |
Apr 2019 |
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review |
Jul 2023 |
Blood Reviews |
Myelodysplastic Syndromes (MDS) |